{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-064792","form_type":"8-K","ticker":"KRRO","cik":"0001703647","company_name":"Korro Bio, Inc.","filed_at":"2025-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.504591+00:00","generated_at":"2026-05-24T03:57:51.998016+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Korro Bio CFO Vineet Agarwal returns from medical leave; Oliver Dolan named principal accounting officer","bullets":["CFO Vineet Agarwal reappointed as principal financial officer effective March 27, ending temporary medical leave since Feb 11.","CEO Ram Aiyar ceases interim CFO duties; remains President and CEO.","Oliver Dolan, SVP Finance, appointed principal accounting officer; granted 20,000-share stock option at closing price.","Option grant effective April 1, 2025; standard indemnification agreement entered."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-064792","json":"https://secwatch.observer/filing/0001193125-25-064792.json","markdown":"https://secwatch.observer/filing/0001193125-25-064792.md","text":"https://secwatch.observer/filing/0001193125-25-064792.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1703647/000119312525064792/0001193125-25-064792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1703647/000119312525064792/d937220d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:57:51.998016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4fee0c9c7c","claim":"Vineet Agarwal was appointed as Chief Financial Officer at Korro Bio, Inc..","evidence_excerpt":"Effective March 27, 2025, Vineet Agarwal, Chief Financial Officer of Korro Bio, Inc., or the Company, ended his temporary medical leave of absence, which had been in effect since February 11, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312525064792/0001193125-25-064792-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"reappointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"5340ecdd9d","claim":"Oliver Dolan was appointed as Principal Accounting Officer at Korro Bio, Inc..","evidence_excerpt":"the Company’s Board of Directors appointed Mr. Oliver Dolan, age 42, current Senior Vice President, Finance, to serve as the Company’s principal accounting officer effective March 27, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312525064792/0001193125-25-064792-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Principal Accounting Officer"}],"fact_type":"executive_change"},{"claim_id":"6c975c7576","claim":"Ram Aiyar changed role as President and Chief Executive Officer at Korro Bio, Inc..","evidence_excerpt":"Dr. Ram Aiyar, who had been serving as the Company’s interim principal financial officer, is no longer serving in that role as of March 27, 2025 and continues to serve as the Company’s President and Chief Executive Officer (principal executive officer).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1703647/000119312525064792/0001193125-25-064792-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"no longer serving"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}